Revefenacin

Revefenacin

Clinical data
Trade names	Yupelri
AHFS/Drugs.com	Monograph
MedlinePlus	a619009
License data	US DailyMed: Revefenacin
Routes of administration	Inhalation
ATC code	R03BB08 (WHO)
Legal status
Legal status	US: ℞-only
Identifiers
CAS Number	864750-70-9
PubChem CID	11753673
DrugBank	DB11855
ChemSpider	9928376
UNII	G2AE2VE07O
KEGG	D10978
Chemical and physical data
Formula	C35H43N5O4
Molar mass	597.760 g·mol−1
3D model (JSmol)	Interactive image
SMILES CN(CCN1CCC(CC1)OC(=O)NC2=CC=CC=C2C3=CC=CC=C3)C(=O)C4=CC=C(C=C4)CN5CCC(CC5)C(=O)N
InChI InChI=1S/C35H43N5O4/c1-38(34(42)29-13-11-26(12-14-29)25-40-19-15-28(16-20-40)33(36)41)23-24-39-21-17-30(18-22-39)44-35(43)37-32-10-6-5-9-31(32)27-7-3-2-4-8-27/h2-14,28,30H,15-25H2,1H3,(H2,36,41)(H,37,43) Key:FYDWDCIFZSGNBU-UHFFFAOYSA-N

Revefenacin, sold under the brand name Yupelri, is a medication for the treatment of chronic obstructive pulmonary disease (COPD). It was approved for use in the United States in 2018. It was developed by Theravance Biopharma and is marketed by Mylan. Revefenacin is formulated as a solution that is nebulized and inhaled.

Revefenacin is a bronchodilator that exerts its effect as a long-acting muscarinic antagonist.

External links

• "Revefenacin". Drug Information Portal. U.S. National Library of Medicine.